As the British government looks to set out its economic plan for the coming months, biotech trade group the BIA has added what it sees as key policies that…

The third quarter saw more money being pumped into the biotech sphere through venture funds than Q2, but the number of deals were slightly down.

After a quiet summer, biotech IPOs are attempting to notch up a few more deals in the autumn, but things remain tough, as AzurRX gets off its IPO, but at a…

The seed-stage fund Breakout Labs has added a new biotech, the skin disorder-focused Azitra, to its growing ranks of “hard science” companies.

In the first quarter after Britain voted to leave the European Union, life sciences deals took a nosedive--and while Asia booked impressive surges in M&A…

Newron Pharmaceuticals has tapped investors for CHF 26.1 million to see it through to data readouts on a couple of key pipeline programs.

Philadelphia, PA-based Immunome has raised $5 million of a Series A round in April that it now said will hit $12.2 million.

Medicxi is putting up €10 million ($11 million) to help Kymo Therapeutics take kynurenine metabolism inhibitors through to clinical proof of concept.

Myovant Sciences and Ra Pharmaceuticals are lining up with IPOs for up to $172.5 million and $86.3 million, respectively.

Venture Capital